Cargando…
Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
BACKGROUND: Although antifibrotic drugs, including nintedanib and pirfenidone, slow the progression of idiopathic pulmonary fibrosis (IPF), there is little data about the timing of start of antifibrotic treatment in real-world clinical practice. The present study aimed to clarify the efficacy of nin...
Autores principales: | Sugino, Keishi, Ono, Hirotaka, Watanabe, Natsumi, Ando, Masahiro, Tsuboi, Eiyasu, Homma, Sakae, Kishi, Kazuma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272304/ https://www.ncbi.nlm.nih.gov/pubmed/34246227 http://dx.doi.org/10.1186/s12890-021-01595-3 |
Ejemplares similares
-
Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
por: Sugino, Keishi, et al.
Publicado: (2021) -
Coronavirus disease 2019 vaccination‐induced acute exacerbation in idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2022) -
Pleuroparenchymal fibroelastosis in mycobacterium avium complex lung disease
por: Sugino, Keishi, et al.
Publicado: (2023) -
Miliary opacities in pulmonary sarcoidosis
por: Sugino, Keishi, et al.
Publicado: (2020) -
Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)